Drug intelligence / Profile preview

nstpbp5185

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

NSTPBP5185 is a novel, orally active, selective thromboxane A2 receptor (TXA2 receptor) antagonist under investigation as an antithrombotic agent. It has demonstrated efficacy in preclinical models by significantly inhibiting thrombus formation and blocking TXA2 receptor-mediated platelet aggregation. Research suggests that NSTPBP5185 may also have beneficial effects on lipid profiles, such as decreasing total cholesterol, LDL-cholesterol, and triglycerides in animal models, highlighting its potential utility in the prevention or treatment of thrombotic and cardiovascular disorders.[4][2]

Targets

TYMP (Thymidine phosphorylase)

Beyond the preview

Go deeper on nstpbp5185.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nstpbp5185.

Explore the full profile